Menu
Contact Us
Subscribe
Menu

ML&P Blog: Our insight into current issues

Medicines Law & Policy periodically will post timely analysis and insight into current events related to intellectual property and innovation policy as they impact on access to medicines. These posts are listed below. We also have a newsletter for those interested in being notified when new articles are posted.

Latest Blog Posts

The new EU compulsory licensing regime needs to allow the export of medicines

Olga Gurgula -
Guest author Olga Gurgula is a Senior Lecturer in Intellectual Property Law at Brunel Law School, Brunel University London. A war-weary Ukraine critically depends on the support of...
Read more

WHO is an essential forum for debates on intellectual property and public health

Ellen 't Hoen -
Recently, Health Policy Watch reported that some European countries at the World Health Organization (WHO) Pandemic Agreement negotiations maintain that intellectual property negotiations belong...
Read more

ML&P’s Statement at the Intergovernmental Negotiating Body on a pandemic accord

Medicines Law & Policy -
This statement was delivered by Kaitlin Mara at the World Health Organization's seventh meeting and drafting group of the Intergovernmental Negotiating Body (INB) to...
Read more

The Urgency of Compulsory Licensing Provision for Transfer of Technology in the Pandemic Treaty: A Case Study on the WHO mRNA Hub

Medicines Law & Policy -
Guest blog by Ronald Eberhard The Intergovernmental Negotiating Body, established by the World Health Assembly, aims to draft a global pandemic prevention, preparedness, and response...
Read more

New reports offer evidence for extending the WTO Decision on TRIPS to Covid-19 therapeutics and diagnostics. Why delay further?

Ellen 't Hoen -
In February 2024, the 13th World Trade Organization (WTO) Ministerial Conference will take place. WTO Members are expected to decide whether to extend the...
Read more

Sharing know-how/trade secrets during a pandemic: We must be planning for it now

Christopher Garrison -
Medicines Law & Policy has recently proposed a provision for inclusion in the draft WHO  pandemic instrument currently being discussed in Geneva (here and...
Read more

Current drafts of the WHO Pandemic Accord lack a provision for access to knowhow/trade secrets. We drafted one.

Medicines Law & Policy -
Negotiations are currently taking place at the World Health Organization (WHO) to conclude a new pandemic agreement by May 2024. The objective of the...
Read more

The European Commission’s proposal on a new EU-wide compulsory licensing regime

Olga Gurgula -
Guest author Olga Gurgula is a Senior Lecturer in Intellectual Property Law at Brunel Law School, Brunel University London A recent international health emergency, the...
Read more

The European Commission’s compulsory licensing proposals are sensible but do not go far enough

Ellen 't Hoen -
An earlier version of this comment was published in Barron's on 21 July 2023. A Spanish translation of it is also available from El...
Read more

Thanks to the European Commission, Biogen can extend Tecfidera monopoly for at least two more years.

Medicines Law & Policy -
According to an investigation by Follow the Money, a Dutch investigative journalism outlet, the European Commission restored the market exclusivity of Tecfidera, a multiple...
Read more

Posts by topic

Medicines Law & Policy

Medicines Law & Policy releases analysis, policy recommendations and tools to aid practitioners working on universal access to medicines. We strive to provide information that is as accurate as possible, and we welcome and encourage feedback. For comments or questions contact us at: office@medicineslawandpolicy.net.

Never miss a post! Sign up for ML&P's mailing list by entering your information below. The list will only be used to inform you of new content (messages are sent approximately once a month).

* indicates required






Medicines Law & Policy will use the information you provide to keep you up-to-date when we post new research and insight. You can change your mind about receiving our newsletter any time by clicking the unsubscribe link in the footer of any email you receive from us. We will treat your information with respect. By clicking below, you agree that we may process your information in accordance with these terms. We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

This work is licensed under Creative Commons. You are free to share, with attribution and without changes, for non-commercial purposes.